Addressing Health Care Disparities and Improving Patient Outcomes in Prostate Cancer: Expert Perspectives on Optimizing ADT
Jointly provided by
Support for this activity has been provided through an educational grant from Pfizer Inc and Myovant Sciences Ltd.
Release date: 3/13/2023
Expiration date: 3/13/2024
Estimated time to complete: 0.75 hour
Prostate cancer is the leading cause of cancer and the second leading cause of cancer death in men in the United States. Medical androgen deprivation therapy (ADT) is the standard of care for advanced prostate cancer but may be associated with a broad range of adverse effects. Increased risk of cardiovascular (CV) events is among the most serious, as CV disease is the most common non-cancer cause of death in prostate cancer patients. Although evidence-based guidelines on ADT selection and CV risk mitigation are available, research has shown that many health care providers (HCPs) are unable to effectively mitigate CV risk in patients receiving ADT for advanced prostate cancer.
Studies also indicate that socioeconomic factors and differences in patterns of care contribute to disparities in prostate cancer outcomes. This is a problematic trend with significant implications for prostate cancer patients who are US Veterans and/or Black, who are at substantially greater risk for worse outcomes due to inequities in care.
This activity has been developed to enhance HCPs’ knowledge and competence regarding selection of appropriate ADT, assessment and management of CV risk, and methods to overcome racial and socioeconomic disparities in advanced prostate cancer care.
Alicia K. Morgans, MD, MPH—Program Co-Chair
Genitourinary Medical Oncologist
Medical Director, Survivorship Program
Dana-Farber Cancer Institute
Neal Shore, MD, FACS—Program Co-Chair
Chief Medical Officer
Urology/Surgical Oncology, GenesisCare
Myrtle Beach, South Carolina
This activity has been designed to meet the educational needs of urologists, medical and radiation oncologists, advanced practice practitioners, and other HCPs who treat patients with advanced prostate cancer, especially clinicians practicing in communities with high Veteran and Black patient populations.
Upon completion of this activity, participants should be better able to:
- Outline the prevalence and disparities in equitable care for US Veterans and Black men with prostate cancer
- Evaluate the benefits and limitations of available ADT options (luteinizing hormone–releasing hormone [LHRH] agonists, gonadotropin-releasing hormone [GnRH] agonists and antagonists) for patients with advanced prostate cancer according to clinical efficacy, CV risk, mechanism of action, and route of administration
- Assess and mitigate CV risk in patients receiving ADT for advanced prostate cancer
- Design an individualized treatment plan that includes the most appropriate ADT according to patient preferences and addresses barriers to equitable care for US Veterans and Black men with advanced prostate cancer
Accreditation and Credit Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati, the Veterans Health and Wellness Foundation, and RedMedEd. The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.
Physician Credit Designation Statement (AMA)
The University of Cincinnati designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
DisclosureIn accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education and the University of Cincinnati policy, all faculty, planning committee members, and other individuals who are in a position to control content are required to disclose all relationships with ineligible companies (commercial interests) within the last 24 months. All educational materials are reviewed for fair balance, scientific objectivity, and levels of evidence. The ACCME requires us to disqualify from involvement in the planning and implementation of accredited continuing education any individuals (1) who refuse to provide this information or (2) whose conflicts of interests cannot be mitigated.
All of the relevant financial relationships listed for these individuals have been mitigated. The following disclosures were made:
Alicia K. Morgans, MD, MPH, has disclosed the following relevant financial relationships:
Consulting: AAA, Astellas, AstraZeneca, Bayer, Dendreon, Exelixis, Janssen, Lantheus, Myriad, Myovant, Novartis, Pfizer, Sanofi, Telix
Research: Astellas, Bayer, Dendreon, Myovant, Pfizer, Sanofi
Neal Shore, MD, FACS, has disclosed the following relevant financial relationships:
Consulting: AbbVie, Alessa Therapeutics, Arquuer, Asieris, Astellas, AstraZeneca, Bayer, Bristol Myers Squibb, Boston Scientific, Clarity, Cold Genesys, Dendreon, Ferring, Foundation Medicine, ImmunityBio, Incyte, Invitae, Janssen, Lantheus, Lilly, Merck, Minoic, Myovant, Myriad, NGM, Nonagen, Novartis, Photocure, Pfizer, Promaxoa, Protara, Sanofi, Sesen Bio, Telix, Tolamr, Vaxxion
University of Cincinnati
Faculty and staff involved in the development and review of this activity have disclosed no relevant financial relationships.
Veterans Health and Wellness Foundation
Evelyn L. Lewis, MD, MA, FAAFP, DABDA, has disclosed the following relevant financial relationships:
The RedMedEd planners have disclosed no relevant financial relationships.
Unapproved Product Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The University of Cincinnati, the Veterans Health and Wellness Foundation, RedMedEd, and Pfizer Inc and Myovant Sciences Ltd do not recommend the use of any agent outside the labeled indications.
The information presented in this activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician regarding diagnosis and treatment of a specific patient’s medical condition.
The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of the University of Cincinnati, the Veterans Health and Wellness Foundation, RedMedEd or Pfizer Inc and Myovant Sciences Ltd. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Method of Participation
There are no fees to participate in the activity. Participants must review all activity information, including the learning objectives, disclosure statements, and content. To receive CME credit, participants must complete the posttest and program evaluation. Certificates can be printed immediately.
For questions regarding CME credit, contact the University of Cincinnati at firstname.lastname@example.org.
For technical questions related to this activity, please contact RedMedEd at 610.251.6841 or email@example.com.
- iPad, iPad Mini (iPadOS 14 or higher), iPhone (iOS 14 or higher), or Android device (OS 11 or higher) with an Internet connection
- Internet browsers: Chrome, Firefox, Safari
- A computer with an Internet connection
- Internet browsers (PC): Chrome, Firefox, Microsoft Edge
- Internet browsers (Mac): Chrome, Firefox, Safari
© 2023. This CME/CE-certified program is held as copyrighted by the University of Cincinnati, the Veterans Health and Wellness Foundation, and RedMedEd. Through this notice, the University of Cincinnati, the Veterans Health and Wellness Foundation, and RedMedEd grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owners.